All News

AAO-HNS Continues Advocacy on Hypoglossal Nerve Stimulation Coverage for Treatment of Obstructive Sleep Apnea (7/20/20)

AAO-HNS Continues Advocacy on Hypoglossal Nerve Stimulation Coverage for Treatment of Obstructive Sleep Apnea (7/20/20)
AAO-HNS Continues Advocacy on Hypoglossal Nerve Stimulation Coverage for Treatment of Obstructive Sleep Apnea (7/20/20)

April 21, 2021

On July 20, the AAO-HNS sent comments to Anthem opposing their medical policy designating hypoglossal nerve stimulation (HGNS) as experimental / investigational for the treatment of obstructive sleep apnea. The Academy requested Anthem revisit and amend its policy given the strong evidence supporting HGNS as efficacious in improving outcomes in patients with OSA.

Related Content

Anthem Announces Extension of Telehealth Flexibility (4/12/21)

Private Payer Advocacy

On April 6, Anthem Blue Cross Blue Shield announced that, until further notice, they will continue to cover telephone-only…

Wellmark Reverses Negative Coverage Policy for Balloon Sinus Ostial Dilation (11/19/20)

Private Payer Advocacy

Following extensive advocacy efforts by the AAO-HNS, the Iowa Academy of Otolaryngology, and other stakeholders, Wellmark revised its medical…

AAO-HNS Comments on Humana’s New Imaging and Interpretation Criteria (11/2/20)

Private Payer Advocacy

On November 2, the Academy sent comments to Humana opposing their new Imaging and Interpretation Criteria for Diagnostic Imaging…

AAO-HNS COVID-19 InformationLearn More